January 15, 2026

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Conexiant

January 14, 2026

Medical Oddities: A Vaccine With a Foam Head?

A week of bold ideas: drinkable vaccines, unrealistic TV CPR, yoga-assisted detox, and meat-heavy math.

Conexiant

November 02, 2023

Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases

Researchers have explored the impact of a combination therapy on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases.

The ASCO Post

November 06, 2024

Weekend Warriors: New Hope for Busy Docs

Almost half of surgeons miss exercise guidelines, but research shows "weekend warriors" achieve similar cardiovascular benefits to those who exercise daily.

Conexiant

November 18, 2024

Diabetes, Amyloid-β Interaction Doubles MCI Risk

Managing diabetes may reduce Alzheimer’s risk, as 20-year data reveal synergistic brain changes from diabetes and amyloid-β abnormality.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

July 26, 2024

EHR Use Disparities: Female vs. Male Surgeons

A recent study published in JAMA Network Open reveals gender differences in electronic health record (EHR) usage among surgeons, with female surgeons writing significantly longer progress notes than their male counterparts.

Conexiant

August 07, 2024

FDA Approves Voranigo for Grade 2 IDH-Mutant Glioma

The FDA's approval of voranigo marks a significant milestone as it becomes the first drug approved in the U.S. for the treatment of Grade 2 IDH-mutant glioma, a type of brain tumor, with promising results in a late-stage clinical trial.

Reuters